2. Search Result
Search Result
Results for "

GLP-1R agonist

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

17

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147625
    GLP-1R agonist 12

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research .
    GLP-1R agonist 12
  • HY-148212
    GLP-1R agonist 17

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1R agonist 17 is a GLP-1 receptor agonist. GLP-1R agonist 17 shows excellent agonism on a GLP-1 receptor. GLP-1R agonist 17 can be used for the research of cardiovascular metabolic diseases .
    GLP-1R agonist 17
  • HY-121835
    GLP-1R agonist 2

    		GCGR Metabolic Disease
    GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity .
    GLP-1R agonist 2
  • HY-161915
    GLP-1R agonist 23

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 23 (Example 376) is a GLP-1R agonist with an EC50 of 0.056 nM. GLP-1R agonist 23 can be used in diabetes research .
    GLP-1R agonist 23
  • HY-168585
    GLP-1R agonist 26

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 26 (compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of <10 nM .
    GLP-1R agonist 26
  • HY-162979
    GLP-1R agonist 25

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 25 (compound 13) is a GLP1-R agonist, with an EC50 of 0.167 nM. GLP-1R agonist 25 can be used in type II diabetes research .
    GLP-1R agonist 25
  • HY-147622
    GLP-1R agonist 9

    		GCGR Metabolic Disease
    GLP-1R agonist 9 (Compound 96) is a GLP-1R agonist with EC50 values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively .
    GLP-1R agonist 9
  • HY-160031
    GLP-1R agonist 19

    		GLP Receptor Cardiovascular Disease
    GLP-1R agonist 19 (M3190) is a potent and selective GLP-1R agonist. GLP-1R agonist 19 has excellent plasma stability, liver microsomal stability, and low hERG toxicity .
    GLP-1R agonist 19
  • HY-162306
    GLP-1R agonist 18

    		GLP Receptor Cancer
    GLP-1R agonist 18 (example 117) is an agonist for GLP-1R with an EC50 of 0.044 nM .
    GLP-1R agonist 18
  • HY-144134
    GLP-1R agonist 6

    		GCGR Metabolic Disease
    GLP-1R agonist 6 is a potent GLP-1R agonist with an EC50 of 0.15 nM for human GLP-1R (WO2021249492A1, compound 005A or 005B) .
    GLP-1R agonist 6
  • HY-144136
    GLP-1R agonist 8

    		GCGR Metabolic Disease
    GLP-1R agonist 8 is a potent GLP-1R agonist with an EC50 of < 2 nM (WO2021219019A1, compound 129a) .
    GLP-1R agonist 8
  • HY-144133
    GLP-1R agonist 5

    		GCGR Metabolic Disease
    GLP-1R agonist 5 is a potent GLP-1R agonist with an EC50 of <10 nM (WO2021259309A1, compound 35) .
    GLP-1R agonist 5
  • HY-144034
    GLP-1R agonist 3

    		GCGR Metabolic Disease
    GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .
    GLP-1R agonist 3
  • HY-144033
    GLP-1R agonist 1

    		GCGR Metabolic Disease
    GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .
    GLP-1R agonist 1
  • HY-144135
    GLP-1R agonist 7

    		GCGR Metabolic Disease
    GLP-1R agonist 7 is a potent GLP-1R agonist with an EC50 of 0.67 µM (WO2021244645A1, compound WXA001) .
    GLP-1R agonist 7
  • HY-144035
    GLP-1R agonist 4

    		GCGR Cancer
    GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) .
    GLP-1R agonist 4
  • HY-147626
    GLP-1R agonist 13

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist .
    GLP-1R agonist 13
  • HY-147628
    GLP-1R agonist 15

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist .
    GLP-1R agonist 15
  • HY-147623
    GLP-1R agonist 10

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 10 (Compound 109a) is a GLP-1 agonist with an EC50 of 0.051 nM .
    GLP-1R agonist 10
  • HY-147629
    GLP-1R agonist 16

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 16 (Compound 115a) is a GLP-1 receptor agonist with an EC50 of 0.15 nM .
    GLP-1R agonist 16
  • HY-147627
    GLP-1R agonist 14

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC50 of 0-20 nM against h-GLP-1 .
    GLP-1R agonist 14
  • HY-162435
    GLP-1R agonist 20

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0162 nM .
    GLP-1R agonist 20
  • HY-162436
    GLP-1R agonist 21

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0104 nM .
    GLP-1R agonist 21
  • HY-162437
    GLP-1R agonist 22

    		GLP Receptor Metabolic Disease
    GLP-1R agonist 22 (Compound I-135) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0165 nM .
    GLP-1R agonist 22
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)

    		GLP Receptor Metabolic Disease
    GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-P10019
    Pegsebrenatide

    NLY01

    		 GCGR Neurological Disease
    Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .
    Pegsebrenatide
  • HY-P10302
    GLP-1R/GIPR agonist-1

    		GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1
  • HY-112679
    GLP-1 receptor agonist 2

    		GCGR Others
    GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.
    GLP-1 receptor agonist 2
  • HY-P3506
    Retatrutide
    1 Publications Verification

    LY3437943

    		 GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
    Retatrutide
  • HY-P3506B
    Retatrutide acetate

    LY3437943 acetate

    		 GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
    Retatrutide acetate
  • HY-P3506A
    Retatrutide TFA
    1 Publications Verification

    LY3437943 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
    Retatrutide TFA
  • HY-P10716
    Exendin-P5

    		GLP Receptor Metabolic Disease
    Exendin-P5 is a selective agonist that targets the GLP-1R. Exendin-P5 promotes rapid activation of G proteins by transient interactions with the transmembrane domain of GLP-1R, enhancing its potency in G protein-mediated signaling and accelerating cAMP production. This mechanism suggests the potential application of Exendin-P5 in the study of metabolic diseases .
    Exendin-P5
  • HY-P4386
    (Asp28)-Exenatide

    		GLP Receptor Metabolic Disease
    (Asp28)-Exenatide is a degradation product of exenatide (HY-13443). (Asp28)-Exenatide can be used as a GLP-1R agonist .
    (Asp28)-Exenatide
  • HY-112185
    Orforglipron
    1 Publications Verification

    LY3502970; GLP-1 receptor agonist 1

    		 GCGR Metabolic Disease
    Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .
    Orforglipron
  • HY-125824
    Danuglipron
    2 Publications Verification

    PF-06882961

    		 GCGR Metabolic Disease
    Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research .
    Danuglipron
  • HY-153865
    Lotiglipron

    PF-07081532

    		 GCGR Metabolic Disease
    Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .
    Lotiglipron
  • HY-125824A
    Danuglipron tromethamine

    PF-06882961 tromethamine

    		 GCGR Metabolic Disease
    Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research .
    Danuglipron tromethamine
  • HY-P3375
    Mazdutide

    IBI-362; LY-3305677; OXM-3

    		 GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
    Mazdutide
  • HY-129657
    GLP-1 receptor agonist 4

    		GCGR Metabolic Disease
    GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC50 of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes .
    GLP-1 receptor agonist 4
  • HY-112185A
    Orforglipron hemicalcium hydrate
    1 Publications Verification

    LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate

    		 GCGR Metabolic Disease
    Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .
    Orforglipron hemicalcium hydrate
  • HY-P3375A
    Mazdutide TFA

    IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA

    		 GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
    Mazdutide TFA
  • HY-P10337
    OXM-7

    		GCGR GLP Receptor Metabolic Disease Endocrinology
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
    OXM-7
  • HY-P3539
    Exendin-4 (3-39)

    		GCGR Neurological Disease Endocrinology
    Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .
    Exendin-4 (3-39)
  • HY-163996
    DD202-114

    		GLP Receptor Metabolic Disease
    DD202-114 is a potent and selective GLP1R agonist. DD202-114 promots cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential for the research of type 2 diabetes (T2DM) and obesity .
    DD202-114
  • HY-120828
    Albenatide

    CJC 1134PC

    		 GLP Receptor Metabolic Disease
    Albenatide (CJC 1134PC) is a modified Exendin-4 (HY-13443) analogue conjugated to human recombinant albumin (HRA) in vitro to form a long-acting DPP-4-resistant GLP-1R agonist. Albenatide covalently binds through a low-molecular chemical linker (cys-C13H19O6N3-lys) to the cysteine residue in position 34 of HRA. Albenatide increases cyclic AMP (cAMP) production in vitro. Albenatide reduces glucose excursions, food intake, gastric emptying in wild-type mice and improves glucose tolerance and reduces body weight in high-fat diet mice .
    Albenatide
  • HY-P3491
    Pegloxenatide

    PEX 168

    		 GLP Receptor Metabolic Disease
    Pegloxenatide is a glucagon-like peptide-1 receptor (GLP-1 RA) agonist. Pegloxenatide can be used for type 2 diabetes research .
    Pegloxenatide
  • HY-138996
    GLP-1 receptor agonist 8

    		GCGR Metabolic Disease
    GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17) .
    GLP-1 receptor agonist 8
  • HY-P5161A
    FC382K10W15 TFA

    		GCGR Metabolic Disease
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
    FC382K10W15 TFA
  • HY-P3291
    Dapiglutide
    1 Publications Verification

    ZP7570

    		 GCGR Metabolic Disease
    Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
    Dapiglutide
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: